<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>-reducing activity and safety of colestilan, a <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrant, in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients with fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) 7.2-11.1 mmol/l and HbA (1c)&gt; or =7.0% were randomly allocated in double-blind manner to receive colestilan or placebo therapy for 12 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 183 patients entered the double-blind treatment phase </plain></SENT>
<SENT sid="3" pm="."><plain>At 12 weeks, colestilan significantly reduced HbA (1c) and FPG vs. placebo by 0.9% and 1.2 mmol/l respectively (both p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>A significant (p &lt; 0.001) 22.5% reduction of <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> was also observed in the 172 patients evaluated (colestilan group: n = 86; placebo group: n = 86) </plain></SENT>
<SENT sid="5" pm="."><plain>However, no significant reduction of fasting insulin was observed (p = 0.087) </plain></SENT>
<SENT sid="6" pm="."><plain>No incidence of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was reported in this study </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Colestilan improved glycaemic control and reduced <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>